Tags

Type your tag names separated by a space and hit enter

Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30; 35(2):380-9.PN

Abstract

Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations. Current therapeutic approaches for the treatment of these disorders are mainly designed towards symptom management and do not manifestly block their typified neuronal loss. However, research conducted over the past decade has reflected the increasing interest and need to find disease-modifying molecules. Among the several neuroprotective agents emerging from experimental animal work, cystamine, as well as its reduced form cysteamine, have been identified as potential candidate drugs. Given the significant benefits observed in a Huntington's disease (HD) model, cysteamine has recently leaped to clinical trial. Here, we review the beneficial properties of these compounds as reported in animal studies, their mechanistic underpinnings, and their potential implications for the future treatment of patients suffering from neurodegenerative diseases, and more specifically for HD and Parkinson's disease (PD).

Authors+Show Affiliations

Centre de Recherche du CHUL (CHUQ), Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, Canada, G1V 4G2.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21111020

Citation

Gibrat, C, and F Cicchetti. "Potential of Cystamine and Cysteamine in the Treatment of Neurodegenerative Diseases." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 35, no. 2, 2011, pp. 380-9.
Gibrat C, Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):380-9.
Gibrat, C., & Cicchetti, F. (2011). Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Progress in Neuro-psychopharmacology & Biological Psychiatry, 35(2), 380-9. https://doi.org/10.1016/j.pnpbp.2010.11.023
Gibrat C, Cicchetti F. Potential of Cystamine and Cysteamine in the Treatment of Neurodegenerative Diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):380-9. PubMed PMID: 21111020.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. AU - Gibrat,C, AU - Cicchetti,F, Y1 - 2010/11/24/ PY - 2010/08/16/received PY - 2010/11/10/revised PY - 2010/11/17/accepted PY - 2010/11/30/entrez PY - 2010/11/30/pubmed PY - 2011/12/13/medline SP - 380 EP - 9 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog. Neuropsychopharmacol. Biol. Psychiatry VL - 35 IS - 2 N2 - Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations. Current therapeutic approaches for the treatment of these disorders are mainly designed towards symptom management and do not manifestly block their typified neuronal loss. However, research conducted over the past decade has reflected the increasing interest and need to find disease-modifying molecules. Among the several neuroprotective agents emerging from experimental animal work, cystamine, as well as its reduced form cysteamine, have been identified as potential candidate drugs. Given the significant benefits observed in a Huntington's disease (HD) model, cysteamine has recently leaped to clinical trial. Here, we review the beneficial properties of these compounds as reported in animal studies, their mechanistic underpinnings, and their potential implications for the future treatment of patients suffering from neurodegenerative diseases, and more specifically for HD and Parkinson's disease (PD). SN - 1878-4216 UR - https://www.unboundmedicine.com/medline/citation/21111020/Potential_of_cystamine_and_cysteamine_in_the_treatment_of_neurodegenerative_diseases_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(10)00450-1 DB - PRIME DP - Unbound Medicine ER -